INAL RESEARCH Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

被引:5
|
作者
Kang, D. -W. [1 ]
Park, S. -K. [2 ]
Yu, Y. L. [3 ]
Lee, Y. [4 ]
Lee, D. H. [5 ]
Kang, S. [3 ,6 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
[8] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
关键词
next-generation sequencing; single-gene testing; non-small-cell lung cancer; distant metastasis; real-world evidence;
D O I
10.1016/j.esmoop.2023.102200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-smallcell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods: This was a retrospective cohort study conducted on patients diagnosed with advanced lung adenocarcinoma between 2017 and 2018 from a nationwide, population-based database. We identified patients who had SGT exclusively (SGT group) or underwent upfront NGS or NGS following SGT as an initial evaluation (NGS group). Patients were followed up until death or the end of the study (31 December 2019). The adjusted hazard ratio (aHR) for death was estimated using the Cox proportional hazards model. The factors affecting the adoption of NGS were identified. Results: Of 8566 patients diagnosed with advanced lung adenocarcinoma, 402 and 6932 patients were assigned to the NGS and SGT groups, respectively. More NGS was carried out in younger patients, those with higher incomes, and those living in urban areas. After balancing these confounders through matching, no difference was observed in the median overall survival and risk of death between the NGS and SGT groups [18.5 versus 19.7 months, log-rank P 1/4 0.783; aHR 0.98, 95% confidence interval (CI) 0.84-1.14, respectively]. Only in a subgroup for whom epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors were not indicated, NGS was associated with better survival outcomes (14.1 versus 9.0 months, log-rank P 1/4 0.006; aHR 0.82, 95% CI 0.69-0.97). Conclusions: In the real world, NGS for all-comers in patients with advanced NSCLC did not increase survival outcomes. When health care resources to support equal access to NGS are limited, upfront SGT followed by NGS may be a more efficient strategy
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer
    Lin, Zeyun
    Li, Yuqin
    Tang, Shiqi
    Deng, Qiuhua
    Jiang, Juhong
    Zhou, Chengzhi
    LUNG CANCER, 2023, 182
  • [32] Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report
    Simarro, Javier
    Perez-Simo, Gema
    Mancheno, Nuria
    Francisco Munoz-Nunez, Carlos
    Cases, Enrique
    Juan, Oscar
    Palanca, Sarai
    DIAGNOSTICS, 2022, 12 (05)
  • [33] The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients
    Cao, Liming
    Long, Long
    Li, Min
    Yang, Huaping
    Deng, Pengbo
    Mao, Xinru
    Xiang, Jianxing
    Li, Bing
    Zhang, Tengfei
    Hu, Chengping
    ONCOTARGETS AND THERAPY, 2018, 11 : 2637 - 2646
  • [34] Poor survival of non-small-cell lung cancer patients with main bronchus tumor: a large population-based study
    Li, Cheng
    Liu, Jia
    Lin, Jiamao
    Li, Zhenxiang
    Shang, Xiaoling
    Wang, Haiyong
    FUTURE ONCOLOGY, 2019, 15 (24) : 2819 - 2827
  • [35] Clinical and economic benefits of using next-generation sequencing (NGS) in the diagnostics of patients with non-small cell lung cancer with rare mutations
    Stencel, Katarzyna
    Wasag, Bartosz
    Pruszko, Cezary
    Dabrowska, Krystyna
    Ksiazek, Pawel
    Dziadek, Karolina
    Bryl, Maciej
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (03): : 201 - 208
  • [36] Dynamic analysis of predictive biomarkers for radiation therapy efficacy in non-small cell lung cancer patients by next-generation sequencing based on blood specimens
    Zhang, Xuemei
    Huang, Xu
    Cao, Yang
    Mao, Yuxin
    Zhu, Yingying
    Zhang, Qian
    Zhang, Tao
    Chang, Lele
    Wang, Chunbo
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 253
  • [37] A population-based study of gefitinib in patients with non-small cell lung cancer
    Kenji Hayashibara
    Hiroaki Satoh
    Yoko Shinohara
    Masaharu Inagaki
    Takayuki Kaburagi
    Toshio Hashimoto
    Koichi Kurishima
    Hiroichi Ishikawa
    Hideo Ichimura
    Takeshi Nawa
    Yasunori Funayama
    Takeshi Matsumura
    Katsunori Kagohashi
    Takeshi Endo
    Kinya Furukawa
    Koji Kishi
    Masaaki Sumi
    Koichi Kamiyama
    Shigemi Ishikawa
    Medical Oncology, 2009, 26 : 222 - 227
  • [38] Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
    Jin, Ying
    Shao, Yang
    Shi, Xun
    Lou, Guangyuan
    Zhang, Yiping
    Wu, Xue
    Tong, Xiaoling
    Yu, Xinmin
    ONCOTARGET, 2016, 7 (38) : 61755 - 61763
  • [39] Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer
    Niu, Lin
    Dang, Chunyan
    Li, Lin
    Guo, Na
    Xu, Ying
    Li, Xiangling
    Xu, Qian
    Cheng, Luyang
    Zhang, Li
    Liu, Lei
    ONCOLOGY LETTERS, 2021, 22 (02)
  • [40] Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
    Kuang, Shelley
    Fung, Andrea S.
    Perdrizet, Kirstin A.
    Chen, Kaitlin
    Li, Janice J. N.
    Le, Lisa W.
    Cabanero, Michael
    Karsaneh, Ola Abu Al
    Tsao, Ming S.
    Morganstein, Josh
    Ranich, Laura
    Smith, Adam C.
    Wei, Cuihong
    Cheung, Carol
    Shepherd, Frances A.
    Liu, Geoffrey
    Bradbury, Penelope
    Pal, Prodipto
    Schwock, Joerg
    Sacher, Adrian G.
    Law, Jennifer H.
    Stockley, Tracy L.
    Leighl, Natasha B.
    CURRENT ONCOLOGY, 2022, 29 (07) : 4428 - 4437